Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)
Saudi Arabia · Delayed Price · Currency is SAR 128.90
-0.30 (-0.23%)
Feb 11, 2026, 3:19 PM AST
TADAWUL:4015 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,456 | 1,318 | 1,101 | 916.67 | 735.68 | 805.31 | |
Revenue Growth (YoY) | 14.83% | 19.77% | 20.09% | 24.60% | -8.65% | 10.06% |
Cost of Revenue | 547.4 | 500.31 | 399.03 | 325.19 | 260.99 | 328.51 |
Gross Profit | 908.36 | 818.17 | 701.79 | 591.49 | 474.69 | 476.81 |
Selling, General & Admin | 407.7 | 385.36 | 350.42 | 314 | 251.89 | 236.89 |
Research & Development | 37.11 | 34 | 33.39 | 32.68 | 37 | - |
Other Operating Expenses | -15.55 | -0.39 | 0.08 | - | - | - |
Operating Expenses | 444.16 | 430.35 | 385.98 | 349.03 | 288.89 | 236.89 |
Operating Income | 464.19 | 387.82 | 315.8 | 242.46 | 185.8 | 239.91 |
Interest Expense | - | -0.1 | -0.11 | -0.12 | - | - |
Interest & Investment Income | 24 | 6.94 | - | - | - | 1.5 |
Earnings From Equity Investments | 17.03 | 18.57 | 4.41 | -0.32 | -0.05 | -0.57 |
Currency Exchange Gain (Loss) | -18.75 | -18.75 | -1.33 | -47.95 | 2.01 | 4.11 |
Other Non Operating Income (Expenses) | -7.3 | -7.3 | -3.02 | -6.54 | 1.28 | -2.88 |
EBT Excluding Unusual Items | 479.17 | 387.18 | 315.76 | 187.53 | 189.04 | 242.08 |
Impairment of Goodwill | - | - | - | - | - | -2.11 |
Gain (Loss) on Sale of Investments | -4.52 | -4.52 | 0.04 | 0.01 | -1.04 | -8.32 |
Gain (Loss) on Sale of Assets | - | - | - | 0.03 | 0.09 | 0.09 |
Asset Writedown | - | - | - | -1.25 | - | - |
Pretax Income | 474.65 | 382.65 | 315.8 | 186.31 | 188.09 | 231.74 |
Income Tax Expense | 27.31 | 26.13 | 23.4 | 15 | 17.39 | 24.88 |
Earnings From Continuing Operations | 447.34 | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 |
Net Income | 447.34 | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 |
Net Income to Common | 447.34 | 356.52 | 292.4 | 171.31 | 170.7 | 206.86 |
Net Income Growth | 28.03% | 21.93% | 70.68% | 0.36% | -17.48% | 31.82% |
Shares Outstanding (Basic) | 70 | 70 | 70 | 70 | 10 | 10 |
Shares Outstanding (Diluted) | 70 | 70 | 70 | 70 | 10 | 10 |
Shares Change (YoY) | - | - | - | 600.00% | - | - |
EPS (Basic) | 6.39 | 5.09 | 4.18 | 2.45 | 17.07 | 20.69 |
EPS (Diluted) | 6.39 | 5.09 | 4.18 | 2.45 | 17.07 | 20.69 |
EPS Growth | 28.03% | 21.93% | 70.68% | -85.66% | -17.48% | 31.82% |
Free Cash Flow | 311.66 | 206.47 | 250.74 | 143.2 | 101.9 | 113.41 |
Free Cash Flow Per Share | 4.45 | 2.95 | 3.58 | 2.05 | 10.19 | 11.34 |
Dividend Per Share | 3.460 | 3.060 | 2.500 | - | - | - |
Dividend Growth | 11.61% | 22.40% | - | - | - | - |
Gross Margin | 62.40% | 62.05% | 63.75% | 64.53% | 64.52% | 59.21% |
Operating Margin | 31.89% | 29.41% | 28.69% | 26.45% | 25.26% | 29.79% |
Profit Margin | 30.73% | 27.04% | 26.56% | 18.69% | 23.20% | 25.69% |
Free Cash Flow Margin | 21.41% | 15.66% | 22.78% | 15.62% | 13.85% | 14.08% |
EBITDA | 505.21 | 424.44 | 341.7 | 266.57 | 209.63 | 281.88 |
EBITDA Margin | 34.70% | 32.19% | 31.04% | 29.08% | 28.49% | 35.00% |
D&A For EBITDA | 41.01 | 36.62 | 25.89 | 24.12 | 23.82 | 41.96 |
EBIT | 464.19 | 387.82 | 315.8 | 242.46 | 185.8 | 239.91 |
EBIT Margin | 31.89% | 29.41% | 28.69% | 26.45% | 25.26% | 29.79% |
Effective Tax Rate | 5.75% | 6.83% | 7.41% | 8.05% | 9.25% | 10.74% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.